REG-Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use
Pharming reported Q2 2026 revenue of $90.2 million, down 3% year-over-year, driven by a 10% decline in RUCONEST sales to $72.3 million, partially offset by a 40% surge in Joenja revenue to $17.9 million. The company revised its full-year 2026 revenue guidance downward to $375 million-$395 million, a reduction of $30 million, while simultaneously improving operating expense guidance by $15 million to reflect cost discipline.
Key figures
- Eps
- 0.003
- Revenue
- 90200000
- Guidance
- 2026 total revenue US$375M-US$395M (reduced by $30M); OpEx US$315M-US$320M (improved by $15M)
- Net income
- 1600000
- Joenja revenue
- 17900000
- Operating profit
- 1300000
- Ruconest revenue
- 72300000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.